Above and beyond establishing a compliance program, a company should create a culture of ethical conduct that permeates day-to-day operations and ensure that it is clearly communicated to all employees and partners.
St. Paul, Minnisota (PRWEB) January 20, 2014
Merrill Brink International (http://www.merrillbrink.com), a leading global provider of language solutions for global companies and law firms, today announced that it has published a new white paper, “Best Practices for Corporate Compliance for Pharmaceutical and Medical Device Manufacturers”.
Recognizing the potential for revenue growth in emerging markets, pharmaceutical and medical device companies are investing heavily in increasing their presence in the global healthcare market. However, just as there is great potential for growth, there is a very real risk related to charges of corruption, particularly for companies as they research, develop, test or market pharmaceutical products or medical devices overseas. As anti-bribery measures grow in importance worldwide, these firms are dealing with bribery charges brought on by multiple countries.
The best way for a company to minimize the risk of prosecution is to put adequate procedures in place to prevent acts of corruption and bribery. Above and beyond establishing a compliance program, a company should create a culture of ethical conduct that permeates day-to-day operations and ensure that it is clearly communicated to all employees and partners.
This means implementing a top-down program of language transparency for communications with employees and partners in all worldwide locations.
Is your company prepared? Is your anti-corruption program as language transparent as it should be? Risk, for pharmaceutical and medical device companies, can arise at multiple points, including the:
Management of foreign clinical trials
Funding of professional development efforts for foreign staff
Selection and management of third party agents and distributors
Management of operating licenses and distribution permits
Gifts offered to foreign entities
Investigations resulting from whistleblowers
Download Merrill Brink’s white paper, “Best Practices for Corporate Compliance for Pharmaceutical and Medical Device Manufacturers,” to learn more about global anti-corruption regulations, the importance of language transparency and how your organization can be optimally prepared for compliance.
About Merrill Brink International
Merrill Brink International (http://www.merrillbrink.com) is a leading provider of complete translation and language solutions for global companies and law firms, with special expertise in serving the legal, financial, life sciences, software, heavy machinery and corporate markets. A proven leader with more than 30 years of experience, Merrill Brink offers a wide range of language solutions including translation, localization, desktop publishing and globalization services.
Merrill Brink is recognized in the industry for its commitment to quality and its pioneering approach of leveraging technology to reduce costs, eliminate redundant processes and accelerate translation life cycles. Merrill Brink is certified to ISO 9001:2008; ISO/IEC 27001:2005 and ISO 13485:2003, and compliant to
EN 15038:2006 and ISO 14971:2007. Together, these standards provide assurance that the most stringent process and quality standards for translation are followed. Merrill Brink International is a wholly owned subsidiary of Merrill Corporation.